The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > IDEC Pharmaceuticals Corporation

IDEC Pharmaceuticals Corporation
Nasdaq: IDPH
Change
symbol:
     
 NEWS FROM THE WIRES
IDEC says its FDA accepts review of Zevalin drug
Aug 02 2001 05:21 AM PDT

IDEC says regulators to review Zevalin Sept. 11
Jul 23 2001 06:27 AM PDT

RPT-Idec Pharmaceuticals Q2 profit rises 71 percent
Jul 19 2001 01:17 PM PDT

Idec Pharmaceuticals Q2 profit rises 71 percent
Jul 19 2001 01:07 PM PDT

INTERVIEW-Taisho bets future on prescription drugs
Jul 18 2001 01:06 AM PDT

More WIRE STORIES about this company

 NEWS FROM THE STANDARD
Late Market Movers: Dow Inches Up, Nasdaq Slips
Nov 27 2000 02:52 PM PST

 PROFILE
IDEC Pharmaceuticals develops treatments for cancer and autoimmune and inflammatory diseases. The company's first FDA-approved product, the best-selling Rituxan, treats non-Hodgkin's lymphoma (NHL). Delivered intravenously, Rituxan is a monoclonal antibody used in place of chemotherapy or radiation treatment. Biotech giant Genentech manufactures Rituxan and is involved in its development and marketing. Through licensing agreements, Hoffmann-La Roche sells Rituxan outside the US and Canada, except in Japan, where Zenyaku Kogyo markets the drug. Lead drug candidate ZEVALIN also targets NHL. IDEC Pharmaceuticals has several more products, including autoimmune candidates, in its pipeline.

 COMPETITION
Agouron Pharmaceuticals, Inc. (dossier)
AstraZeneca PLC (AZN)
Immunex Corporation (IMNX)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 154.70
1-Yr. Sales Growth: 31.1%
Employees: 493
Revenue per employee: $313,793.10

 KEY PEOPLE
• William H. Rastetter
    CEO
• Phillip M. Schneider
    CFO

 CONTACT INFO
3030 Callan Rd.
San Diego, CA 92121
US
Phone: 858-431-8500
Fax: 858-431-8750
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001